Skip to content

Ibogaine

A psychoactive alkaloid researched chiefly for its potential to interrupt opioid and stimulant dependence.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Ibogaine, iboga, noribogaine, then ranked by relevance.

Ibogaine shows preliminary evidence for reducing opioid withdrawal symptoms and drug craving, with several observational studies and case series reporting rapid detoxification and sustained abstinence in some individuals. However, the evidence is limited by small sample sizes, lack of randomized controlled trials, and significant safety concerns including neurotoxicity in animal models and risk of cardiac arrhythmia and death, particularly during opioid detoxification. The overall evidence is insufficient to support clinical use without rigorous safety monitoring.

Confidence in the evidence

Low
  • Only three RCTs identified, with small sample sizes and mixed results; most evidence from observational studies and case series.
  • Animal studies consistently show neurotoxic effects (Purkinje cell degeneration) and tremor, raising safety concerns.
  • Large retrospective study (19,071 patients) found mortality concentrated in opioid detoxification, but absolute rate is low and non-adjudicated.
  • Inconsistent findings on durability of effect: some studies show sustained abstinence, others show relapse within days to weeks.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport. 2019
Unclear

Ibogaine noncompetitively inhibits serotonin transport by stabilizing the cytoplasm-facing state of SERT, providing a structural mechanism for its psychoactive and anti-addictive properties.

preclinical

Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. 1993
Opposes

Ibogaine and harmaline cause degeneration of Purkinje cells in parasagittal stripes of the cerebellar vermis in rats, indicating selective neurotoxicity.

preclinical

Treatment of acute opioid withdrawal with ibogaine. 1999
Supports

Resolution of opioid withdrawal signs within 24 hours in 25 of 33 patients, sustained over 72 hours, with one fatality possibly due to surreptitious heroin use.

observational Sample size: 33

Effects and aftereffects of ibogaine on morphine self-administration in rats. 1991
Supports

Ibogaine dose-dependently decreased morphine self-administration acutely and produced persistent decreases for days to weeks in some rats, with no aftereffect on water-reinforced responding.

preclinical

Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. 1994
Supports

Ibogaine and several iboga alkaloids dose-dependently decreased morphine and cocaine self-administration acutely, with some producing aftereffects the next day; tremorigenic activity was noted.

preclinical

The ibogaine medical subculture. 2008
Supports

68% of individuals took ibogaine for substance-related disorders, 53% specifically for opioid withdrawal, indicating widespread use for detoxification despite lack of clinical standards.

observational Sample size: 3414

Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption 2005
Supports

Ibogaine decreased ethanol self-administration in rats and increased GDNF expression in the VTA; intra-VTA GDNF mimicked and anti-GDNF antibodies reduced the effect, identifying a molecular mechanism.

preclinical

Inhibitory effects of ibogaine on cocaine self-administration in rats. 1993
Supports

A single injection of ibogaine (40 mg/kg) significantly decreased cocaine intake for over 48 hours, with repeated weekly injections producing more prominent inhibition.

preclinical

A preliminary investigation of ibogaine: case reports and recommendations for further study. 1994
Supports

Single doses of 700-1800 mg ibogaine eliminated opiate withdrawal symptoms; three of seven remained drug-free for 14 weeks or more, while others relapsed after days to weeks.

observational Sample size: 7

The Olivocerebellar Projection Mediates Ibogaine-Induced Degeneration of Purkinje Cells: A Model of Indirect, Trans-Synaptic Excitotoxicity 1997
Opposes

Ibogaine-induced Purkinje cell degeneration is indirect and dependent on integrity of the olivocerebellar projection, consistent with excitotoxic mechanism via climbing fiber activation.

preclinical

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. 2018
Supports

Ibogaine significantly reduced opioid withdrawal scores acutely; at 1-month follow-up, 50% reported no opioid use in prior 30 days, with sustained improvement in drug use scores over 12 months.

observational Sample size: 30

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. 2018
Supports

Significant reductions in addiction severity and depression scores from baseline to 12-month follow-up after a single ibogaine treatment; acute withdrawal symptoms also reduced.

observational Sample size: 14

Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter. 2007
Unclear

Ibogaine noncompetitively inhibits serotonin transport by stabilizing the cytoplasm-facing state of SERT, contrasting with cocaine's mechanism.

preclinical

Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. 2000
Supports

Ibogaine significantly decreased craving for cocaine and heroin during inpatient detoxification and reduced depressive symptoms at 30 days post-discharge; complex pharmacokinetics noted.

observational

Ibogaine possesses a selective affinity for sigma 2 receptors. 1995
Unclear

Ibogaine has relatively high affinity for sigma-2 receptors (Ki=90.4 nM) and much lower affinity for sigma-1 receptors (Ki=9310 nM), suggesting a novel mechanism.

preclinical

Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology 2026
Unclear

Ibogaine shows therapeutic potential across substance use disorders, trauma, mood disorders, and suicidality, but clinical translation is hindered by safety concerns, regulatory barriers, and complex pharmacology.

review

MiSAM opposes bill giving $50 million in opioid settlement funds to ibogaine research 2026
Opposes

The Michigan Society of Addiction Medicine opposed a bill allocating $50 million in opioid settlement funds to ibogaine research, indicating professional skepticism.

other

Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain. 2026
Unclear

A validated UPLC-MS/MS method was developed to quantify ibogaine, noribogaine, ibogamine, and oxa-noribogaine in rat brain microdialysate, enabling real-time neuropharmacokinetic monitoring.

preclinical

Indication-stratified mortality risk of ibogaine treatment under contemporary safety protocols: a multisite analysis of 19,071 patients and updated systematic review of fatalities 2026
Opposes

Six deaths occurred within 72 hours among 10,382 opioid use disorder patients, with none among 8,689 non-SUD patients; mortality risk is concentrated in opioid detoxification.

observational Sample size: 19071

Physarum-Mediated Biofeedback Rehabilitation: A Bio-Hybrid Framework for Ibogaine-Assisted Neural Recovery 2026
Unclear

A bio-hybrid framework using Physarum-mediated biofeedback for ibogaine-assisted neural recovery is proposed as a defensive publication, with no empirical data.

theoretical

Uso da ibogaína no tratamento da dependência química: uma revisão de literatura 2026
Mixed

Ibogaine shows multimodal action and potential for reducing withdrawal and craving, but safety remains the main limitation due to QTc prolongation, arrhythmias, and cardiac events.

review

Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series 2026
Supports

An integrative iboga microdosing protocol (estimated 3.8-38.5 mg/day ibogaine) paired with psychotherapy was associated with clinical improvement in three cases of brain injury.

observational Sample size: 3

Exploring the Use of Ibogaine in Opioid Recovery: Insights from Lived Experience 2026
Supports

Participants associated ibogaine treatment with rapid detoxification, improved mood, reduced anxiety, and periods of sustained abstinence, though relapse occurred in some cases.

qualitative Sample size: 10

Ibogaine induces juvenile-like plasticity and modulates functional and structural regulators of plasticity in the adult mouse visual cortex. 2026
Supports

A single dose of ibogaine (40 mg/kg) reinstated juvenile-like experience-dependent plasticity in the adult mouse visual cortex, reducing perineuronal nets and inhibitory synaptic markers.

preclinical

From monotherapy to sequential models: An updated scoping review on ibogaine’s role in treatment for psychiatric disorders 2026
Mixed

Only three RCTs were identified: one showed reduced cocaine craving, one found noribogaine safe in healthy volunteers, and one showed QTc prolongation with non-significant withdrawal reduction in opioid-dependent patients.

review

Points of agreement

  • Multiple observational studies and case series report that ibogaine reduces opioid withdrawal symptoms acutely.
  • Preclinical studies consistently show that ibogaine decreases self-administration of morphine, cocaine, and ethanol in rats.
  • Ibogaine has complex pharmacology, including inhibition of serotonin transport, sigma-2 receptor affinity, and GDNF upregulation.
  • Safety concerns are consistently noted: neurotoxicity in animal models (Purkinje cell degeneration) and cardiac risk (QTc prolongation, arrhythmias) in humans.

Conflicts

  • Durability of effect varies widely: some studies report sustained abstinence for months, while others show relapse within days to weeks.
  • The large retrospective study (27250) found mortality only in opioid detoxification, but other studies report no deaths or attribute fatalities to surreptitious drug use.
  • Professional organizations (e.g., MiSAM) oppose funding ibogaine research, while other researchers advocate for its development with safety protocols.

Gaps

  • No large, double-blind, placebo-controlled RCTs of ibogaine for opioid use disorder exist.
  • Long-term safety data, especially regarding cardiac and neurological effects, are lacking.
  • Optimal dosing, route of administration, and patient selection criteria are not established.
  • The role of active metabolites (e.g., noribogaine) and their contribution to efficacy and toxicity is unclear.
  • Most studies are small, open-label, or observational, with high risk of bias and lack of standardized outcome measures.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Ibogaine, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Ibogaine or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: June 2026 →

587 articles · 115 from the last two years · 47,065 participants across 109 studies reporting sample size

Common study designs

review 109 preclinical study 17 systematic review 23 experimental study 113 theoretical or philosophical paper 22

Research

Synthesize the evidence → Search all →

Development of Bioisosteric Iboga -alkaloids as Antinociceptive and Anxiolytic Agents with Neuroprotective Effects

Abhishek Gupta, Tuhin Bhattacharya, Subhamoy Pratihar et al. preprint

Iboga alkaloids can reverse drug addiction and modulate drug tolerance but cause severe hallucinogenic effects and cardiotoxicity by blocking the hERG potassium channel. Researchers synthesized four new benzofuran-containing iboga analogs (C1, C2, C3, C4) with a bio-isosteric replacement of indole with benzofuran. The Endo-iboga analogs (C2 and C4) showed superior anti-inflammatory and oxidative stress-relieving activity and improved restricted locomotor activity in a formalin-induced acute pain model in mice. They elevated levels of GABA, dopamine, and BDNF. C4 had a superior cardiac safety profile in C2C12 cells (IC50 = 235 µM) and caused no significant QTc prolongation in rat ECG tests, indicating potential for acute pain management without notable cardiotoxicity.

DOI: 10.1101/2025.02.24.639821

JNDS, Volume 16, Number 1

University of North Texas Digital Library (University of North Texas) Bianchi

Ketamine can produce experiences resembling near-death experiences (NDEs), but the nature of these experiences differs depending on the context—recreational use versus use in an operating room. Both ketamine and ibogaine, a substance used in Central African religious rituals to induce NDEs, are noncompetitive antagonists of the NMDA receptor. Ibogaine also elicits different experiences based on whether it is used in a hallucinatory context or in initiatic rituals that induce a superficial coma. These observations raise the question of whether the chemically-induced NDE-like experience stems from the specific substance or from the genuine comatose state itself.

DOI: 10.17514/jnds-1997-16-1-p71-78 Ketamine Nmda receptor Psychology Neuroscience +1

traditional use of hallucinogenic plants in Africa

Revista de Arqueología Americana July 10, 2026 Giorgio Samorini

For decades, scholars believed the Old World had far fewer psychoactive plants in traditional use than the New World, attributing this to cultural differences. However, recent research in Africa reveals a wealth of traditional uses of hallucinogenic plants that had been overlooked due to a lack of ethnobotanical investigation. These plants are primarily employed in possession states, serving adorcist or exorcist functions, and often for healing. Examples include the Bori cult of the Hausa in Niger, female initiation rites of the Tsonga in Mozambique, the Fang cult of Byeri, iboga cults in western equatorial Africa, divinatory practices like the misoko of the Mitsogho in Gabon and sangoma in South Africa, and as a truth serum in judicial investigations such as the leba shay of Abyssinia.

DOI: 10.35424/rearam.i44.6065 Shamanism Ethnobotany Hausa Cult +9

Psychedelics and the thalamocortical system: A scoping review

Pharmacology Biochemistry and Behavior July 9, 2026 Sofía Villalba, Agustín Martínez Christensen, Lucia di Costanzo et al.

Psychedelics show promise as therapeutic interventions for depression, terminal illnesses, substance use disorder, neurodegenerative diseases, trauma, and obsessive-compulsive disorder. Research on psychedelics has advanced understanding of the neurobiological mechanisms behind the 'psychedelic state of consciousness' and both physiological and pathological thalamocortical functioning. Several psychiatric conditions—such as depression, schizophrenia, bipolar disorder, and autism—involve alterations in the thalamocortical system, so deeper understanding of thalamic function could significantly impact psychedelic research and biological psychiatry. This scoping review (using the PRISMA method) synthesizes preclinical and clinical evidence on effects of psychedelics (NMDA receptor antagonists, serotonin 2A receptor agonists, and mixed-pharmacology compounds like iboga alkaloids) on the thalamocortical system, suggesting its importance for clinical practice and understanding psychedelic neurobiology.

DOI: 10.1016/j.pbb.2026.174232 Serotonin Thalamus Pathological Clinical practice +5

Maria Sabina-Die enteignete Heilerin / Vier Enteignungen, ein Muster

Zenodo (CERN European Organization for Nuclear Research) July 8, 2026 Schüller Thomas

Two works examine the appropriation of Indigenous healing practices. The first, 'Die enteignete Heilerin' (The Expropriated Healer), focuses on the Mazatec shaman Maria Sabina, whose use of psilocybin mushrooms was co-opted by outsiders. The second, 'Vier Enteignungen, ein Muster' (Four Expropriations, One Pattern), compares the appropriation of peyote, ayahuasca, salvia, and iboga, arguing that a common pattern of colonial and capitalist expropriation underlies these cases.

DOI: 10.5281/zenodo.21252639 Theme computing Subject documents Context archaeology Art

Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology

Expert Opinion on Drug Discovery July 4, 2026 Christopher D. Verrico, Lynnette A. Averill, Cameron J Moore et al.

Ibogaine, a natural alkaloid, shows potential for treating substance use disorders, trauma, mood disorders, and suicidality, but clinical use is limited by safety concerns and regulatory barriers. Researchers are pursuing two main strategies: developing ibogaine-like compounds that keep broad effects while reducing risks, and creating selective 'bespoke' analogs targeting specific conditions like opioid use disorder, traumatic brain injury, or PTSD. The authors emphasize that the field should avoid oversimplified views that derivatives are uniformly better or interchangeable, and call for greater conceptual clarity and mechanistic humility as ibogaine-based therapies move toward regulated medical use.

DOI: 10.1080/17460441.2026.2693144 Addiction Clarity Drug development Psychopharmacology +7

The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review

Journal of Psychopharmacology June 26, 2026 Flavia Giaffone de Paiva Ferreira, João Ariel Bonar Fernandes, Renato Filev et al.

A scoping review categorized psychosocial protocols used in psychedelic research for mental health treatment. Seven categories were defined, reflecting distinct emphases on the substance, participant, research team, and sociocultural context. Although limited reporting and heterogeneity remain methodological challenges, the proposed parameters suggest a shared language to describe, compare, and examine psychosocial protocols across studies, reducing conceptual uncertainty. The review may facilitate research decision-making and support structured, replicable study designs while allowing flexibility for individualized and culturally responsive care. Explicitly defining the intended purpose of psychosocial protocols could improve transparent reporting and evaluation.

DOI: 10.1177/02698811261453850 Psychosocial Categorization Observational study Flexibility engineering +15

Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain.

Journal of pharmaceutical and biomedical analysis June 24, 2026 Scot Mcintosh, Isabella Maldonado, Nickalus C Smith et al.

A sensitive UPLC-MS/MS method was developed and validated to quantify ibogaine, noribogaine, ibogamine, and oxa-noribogaine in rat brain microdialysate, measuring pharmacologically active, unbound drug in brain extracellular fluid rather than total tissue content. The method achieved lower limits of quantification of 0.78-1.56 ng/mL with a 6-minute run time, and calibration curves were linear over 0.78-75 ng/mL for ibogamine and 1.56-75 ng/mL for the other analytes. Accuracy and precision met acceptance criteria. Applied to rats (n=4), noribogaine in nucleus accumbens after 10 mg/kg intraperitoneal administration reached a peak unbound concentration of 292 ± 68 ng/mL at 50 minutes, demonstrating suitability for real-time neuropharmacokinetic profiling of iboga alkaloids.

DOI: 10.1016/j.jpba.2026.117630 Full text Bioanalytical method validation Brain microdialysis Iboga alkaloids Neuropharmacokinetics +1

Indication-stratified mortality risk of ibogaine treatment under contemporary safety protocols: a multisite analysis of 19,071 patients and updated systematic review of fatalities

Research Square June 17, 2026 Martijn Arns, Kenneth Shinozuka, Joseph Barsuglia

Ibogaine, a substance showing early promise for treating substance use disorders and PTSD in veterans, carries a risk of cardiac arrhythmia and death. A retrospective multisite study of 19,071 patients treated under safety guidelines at 11 international clinics found that all six deaths occurring within 72 hours were among patients treated for opioid use disorder (6 out of 10,382), with no deaths among 8,689 non-SUD patients. A systematic review of ibogaine-associated fatalities mirrored this pattern: 41 of 44 fatalities with known indication involved substance use disorder, predominantly opioid detoxification. The findings indicate that ibogaine-associated mortality is largely confined to opioid detoxification and rare in non-SUD indications.

DOI: 10.21203/rs.3.rs-9966269/v1 Full text Opioid use disorder Detoxification alternative medicine Poison control Mortality rate +7

Clinical trials

All Ibogaine trials →